Companies › Xiamen Innovax Biotech
1 active drug program in 2 registered trials: 2 Phase 4; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vacc 9-valent HPV vaccine (recombinant viral-like particles for HPV types 6, 11, 16, 18, 31, 33 | – | Phase 4 | Infection by Human Papilloma Virus; HPV Infection | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07668271 | Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vacc | Phase 4 | Infection by Human Papilloma Virus | Infectious disease | Feb 2027 |
| NCT07281677 | Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vacc | Phase 4 | HPV Infection | Infectious disease | Dec 2028 |
No annotated target.
–
NPO Petrovax National Vaccine and Serum Institute, China ARJ Medical MAXVAX Biotechnology Limited Liability Company Biothervax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.